Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium thiosulfate for cisplatin-induced ototoxicity in hepatoblastoma
NCT00652132Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Dec 2007
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sodium thiosulfate in ototoxicity, sponsored by University of Birmingham. Primary endpoint: Rate of Brock grade ≥ 1 hearing loss at 3.5 years. Started Dec 2007; status: completed.
02
Drugs
sodium thiosulfate
03
Conditions
ototoxicity
Beyond the preview
Go deeper on NCT00652132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00652132.